Abstract
Background: Parotid malignancies represent a heterogeneous group of tumors primarily managed by surgical extirpation. Moderately high recurrence rates are seen after surgery alone, and postoperative radiotherapy has been used for patients with higher risks for local failure.
Methods: To assess the role of radiotherapy in the management of patients with malignant tumors of the parotid gland, the records of 68 patients receiving megavoltage therapy at our institution from 1966 to 1989 were reviewed. Patients were placed into three groups for analyses. Group I was composed of 41 patients receiving radiotherapy following total gross removal of parotid cancer by surgical procedures, varying from excisional biopsy through total parotidectomy. Radiation dose for this group ranged from 4,995 to 6,500 cGy. Group II was composed of 10 patients treated with radiotherapy after incisional biopsy or excision with positive margins. These patients received radiation doses of 4,000–9,470 cGy. Group III was composed of 17 patients receiving radiotherapy for a postsurgical local recurrence. Their radiation dose ranged from 4,300 to 8,400 cGy.
Results: Two of the 41 patients from group I developed a local recurrence. Two of these patients also developed distant metastases, one concurrent. Two of 10 group II patients failed locally, whereas three developed distant metastases. Only nine of the 17 patients in group III were controlled locally, and four patients developed distant dissemination.
Conclusion: Total gross excision of parotid cancer, sparing facial nerve if possible and followed by regional radiotherapy, provides excellent rates of local control and survival with modest toxicity. Patients presenting postoperatively with gross residual tumor or recurrence after surgery should be considered for trials of more aggressive treatment with combined chemotherapy or altered fractionation schemes of irradiation.
Similar content being viewed by others
References
Spiro RH. Diagnosis and pitfalls in the treatment of parotid tumors.Semin Surg Oncol 1991;7:20–4.
Spiro RH. Salivary neoplasms: overview of a 35 year experience with 2807 patients.Head Neck Surg 1986;8:177–84.
Bortline A, Kjellevold K, Kalhus O, Vermund H. Salivary gland neoplasms: treatment and prognosis.Int J Radiat Oncol Biol Phys 1986;12:747–54.
Fu KK, Leibel SA, Levine MD, Friedlander LM, Boles R, Phillips TL. Carcinoma of the major and minor salivary glands: analysis of treatment results and sites and causes of failures.Ca 1977;40:2882–90.
Kagan AR, Nussbaum H, Handler S. Recurrences from malignant parotid gland tumors.Ca 1976;37:2600–4.
Rafla S. Malignant parotid tumors: natural history and treatment.Ca 1977;40:136–44.
Shidnia H, Hornback NB, Hammaker R, Lingeman R. Carcinoma of major salivary glands.Ca 1980;45:693–7.
Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY. Malignant tumors of major salivary gland origin: a matched pair analyses of the role of combined surgery and postoperative radiotherapy.Arch Otolaryngol Head Neck Surg 1990;116:290–3.
Caliaro C. In: Le masse della regione parotidae. Semeilogia e Clinica.Acta Otorhinolaryngol Ital 1984;4:368–70.
Dobrowski W, Schlappack O, Carcher KH, Pavelka R, Kment G. Electron beam therapy in treatment of parotid neoplasms.Radiother Oncol 1986;6:293–9.
Guillamondegui OM, Byers RM, Luna MA, Chiminazzo H, Jesse RH, Fletcher GH. Aggressive surgery in treatment of parotid cancer: the role of adjunctive postoperative radiotherapy.AJR 1975;123:49–54.
Imperato JP, Wichselbaum RR, Ervin PJ. The role of post-operative radiation therapy in the treatment of malignant tumors of the parotid gland.J Surg Oncol 1984;27:153–67.
Vikram B, Strong EW, Shah JP, Spiro RH. Radiation therapy in adenoid cystic carcinoma.Int J Radiat Oncol Biol Phys 1984;10:221–3.
Dembrow V. Editor's remarks.Surg Oncol 1991;7:2.
Cutler SJ, Ederer F. Maximum utilization of life table method in analyzing survival.J Chron Dis 1958;8:699–713.
Lee E, Desu M. A computer program for comparing K samples with right censored data.Comp Prog Biomed 1972;2:315–21.
King JJ, Fletcher GH. Malignant tumors of the major salivary glands.Radiology 1971;100:318–84.
McNaney D, McNeese M, Guillamondegui OM, Fletcher GH, Donald MJ. Postoperative irradiation in malignant epithelial tumors of the parotid.Int J Radiat Oncol Biol Phys 1983;9:1289–95.
Fitzpatrick PJ, Theriault C. Malignant salivary gland tumors.Int J Radiat Oncol Biol Phys 1986;12:1743–7.
Spiro RH, Huvos AG, Strong EW. Cancer of the parotid gland, clinical pathology study of 288 primary cases.Am J Surg 1975;130:452–9.
Fitzpatrick PJ, Black KM. Salivary gland tumors.J Otolaryngol 1985;14:296–300.
Vikram B, Strong EW, Shah JP, Spiro RH. Radiation therapy in adenoid cystic carcinoma.Int J Radiatat Oncol Biol Phys 1984;10:221–3.
Maor MH, Hussey DH, Fletcher GH, Jesse R. Fast neutron therapy for locally advanced head and neck tumors.Int J Radiat Oncol Biol Phys 1981;7:1667–71.
Duncan W, Orr JA, Arnott SJ, Jack WJL. Neutron therapy for malignant tumors of the salivary glands. A report of the Edinburgh experience.Radiother Oncol 1987;8:97–104.
Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY. Observations on the natural history and treatment of recurrent major salivary gland cancer.J Surg Oncol 1990;44:138–41.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Toonkel, L.M., Guha, S., Foster, P. et al. Radiotherapy for parotid cancer. Annals of Surgical Oncology 1, 468–472 (1994). https://doi.org/10.1007/BF02303611
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02303611